Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
Novel Embolizing Therapy for the Ablation of Solid Tumors (Ref # WFU 11-47)
Wake Forest Innovations USA flag USA
Abstract ID:
Technology is the first to combine nanoparticles, radiofrequency, and embolization to destroy cancerous tissue and treat vascular-related disorders in a highly specific manner....
Contact Charlie Shaw
Participants
You
Email me a copy of this message

Novel Embolizing Therapy for the Ablation of Solid Tumors


Value Proposition


A common issue in the treatment of cancer is the unregulated toxic effects many therapies elicit on healthy tissues, without fully destroying the entire tumor. In addition, while studies show effective cell death with nanoparticle-based technologies, these particles frequently leech out of the target site into unintended regions of the body. This is due to the lack of a developed fixing agent to maintain nanoparticles locally in the tissue. This technology is the first to combine nanoparticles, radiofrequency, and embolization to destroy cancerous tissue and treat vascular-related disorders in a highly specific manner.


Invention Summary


Researchers have developed a technology that combines a nanoparticle-embedded embolizing agent with radiofrequency-stimulated thermal ablation to destroy vascularized tumors or unhealthy tissues.


Competitive Benefits


•       Guided localization of the emboli-nanoparticle agent endovascularly ensures specific radiofrequency-induced tissue destruction without affecting the surrounding healthy tissue.


•        Unlike other nanoparticle therapies, the nanoparticles utilized in this technology remain fixed within the embolizing agent to prevent systemic escape and undesired toxic effects on the body.  


Application Fields


•       Treatment of tumorigenic cancers, especially those that are highly vascularized


•        Treatment of vascular disorders such as arteriovenous malformations and cerebral aneurysms


•       Prevention or treatment of tissue bleeding and hemorrhaging


 Stage of Development


•       Preclinical studies in porcine and nonhuman primate models show 100 percent success rates in localized delivery of the technology to the renal artery.


•        The technology effectively ablates specific regions of animal kidney tissue, while the surrounding tissue remains unaltered.


•        Larger-scale animal studies will be conducted to further validate the effects of the technology on renal tissue.


•        Optimization of thermal gradients and radiofrequency power in an in vitro model will be initiated soon.


Background


•       Toxic non-specific effects on healthy tissue frequently occur with standard treatments of cancer such as chemotherapy, immunotherapy and radiotherapy.


•        The use of nanoparticles alone to induce cell death also shows a lack of target specificity and a greater need for radiation levels that are dangerously high to destroy tissue.


•        Embolization is the occlusion of blood flow to induce tissue necrosis and death, commonly used for the treatment of vascular disorders.


Inventors



  • David L. Carroll, PhD


Physics



  • Joel L. Berry, PhD 


Biomedical Engineering



  • Pierre H. Rolland, PhD


Physiology


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 

GO PREMIUM TO GET PATENT INFORMATION
Type of Business Relationship Sought

 

Exclusive Licensing Arrangement

Possibility of a parallel Sponsored Research Agreement

Contact 

Charlie Shaw, PhD

Wake Forest Innovations

Commercialization Associate

Tel:  +1.336.716.3729

Email: chshaw@wakehealth.edu

 

 

FEATURED
Last Updated Feb 2014
Technology Type THERAPEUTIC
Phase of Development PRECLINICAL
CORPORATION